TY - JOUR
T1 - Early Experiences With COVID-19 Testing in Transplantation
AU - Boyarsky, Brian J.
AU - Massie, Allan B.
AU - Love, Arthur D.
AU - Werbel, William A.
AU - Durand, Christine M.
AU - Avery, Robin K.
AU - Jackson, Kyle R.
AU - Kernodle, Amber B.
AU - Thomas, Alvin G.
AU - Ronin, Matthew
AU - Altrich, Michelle
AU - Niles, Patricia
AU - Trahan, Chad
AU - Hewlett, Jonathan
AU - Segev, Dorry L.
AU - Garonzik-Wang, Jacqueline M.
N1 - Publisher Copyright:
© 2020 Wolters Kluwer Health. All rights reserved.
PY - 2020/7/11
Y1 - 2020/7/11
N2 - Background. The early effects of coronavirus disease 2019 (COVID-19) on transplantation are dramatic: >75% of kidney and liver programs are either suspended or operating under major restrictions. To resume transplantation, it is important to understand the prevalence of COVID-19 among transplant recipients, donors, and healthcare workers (HCWs) and its associated mortality. Methods. To investigate this, we studied severe acute respiratory syndrome coronavirus 2 diagnostic test results among patients with end-stage renal disease or kidney transplants from the Johns Hopkins Health System (n = 235), and screening test results from deceased donors from the Southwest Transplant Alliance Organ Procurement Organization (n = 27), and donors, candidates, and HCWs from the National Kidney Registry and Viracor-Eurofins (n = 253) between February 23 and April 15, 2020. Results. We found low rates of COVID-19 among donors and HCWs (0%-1%) who were screened, higher rates of diagnostic tests among patients with end-stage renal disease or kidney transplant (17%-20%), and considerable mortality (7%-13%) among those who tested positive. Conclusions. These findings suggest the threat of COVID-19 for the transplant population is significant and ongoing data collection and reporting is critical to inform transplant practices during and after the pandemic.
AB - Background. The early effects of coronavirus disease 2019 (COVID-19) on transplantation are dramatic: >75% of kidney and liver programs are either suspended or operating under major restrictions. To resume transplantation, it is important to understand the prevalence of COVID-19 among transplant recipients, donors, and healthcare workers (HCWs) and its associated mortality. Methods. To investigate this, we studied severe acute respiratory syndrome coronavirus 2 diagnostic test results among patients with end-stage renal disease or kidney transplants from the Johns Hopkins Health System (n = 235), and screening test results from deceased donors from the Southwest Transplant Alliance Organ Procurement Organization (n = 27), and donors, candidates, and HCWs from the National Kidney Registry and Viracor-Eurofins (n = 253) between February 23 and April 15, 2020. Results. We found low rates of COVID-19 among donors and HCWs (0%-1%) who were screened, higher rates of diagnostic tests among patients with end-stage renal disease or kidney transplant (17%-20%), and considerable mortality (7%-13%) among those who tested positive. Conclusions. These findings suggest the threat of COVID-19 for the transplant population is significant and ongoing data collection and reporting is critical to inform transplant practices during and after the pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85090115153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090115153&partnerID=8YFLogxK
U2 - 10.1097/TXD.0000000000001024
DO - 10.1097/TXD.0000000000001024
M3 - Article
C2 - 32766427
AN - SCOPUS:85090115153
SN - 2373-8731
VL - 6
SP - E572
JO - Transplantation Direct
JF - Transplantation Direct
IS - 7
ER -